ISS And Glass Lewis Support Ikena's Share Issuance For Proposed Inmagene Merger

Written by Emily J. Thompson, Senior Investment Analyst

IKNA%

Source: NASDAQ.COM

Updated: Jul 11 2025

0mins

Source: NASDAQ.COM

Merger Recommendation: Ikena Oncology has received recommendations from ISS and Glass Lewis for shareholders to approve the issuance of shares for its merger with Inmagene Biopharmaceuticals, set to be voted on during the Annual Meeting on July 15, 2025.
Drug Development Insight: Inmagene is developing IMG-007, an anti-OX40 monoclonal antibody currently in a Phase 2B trial for atopic dermatitis, which Ikena's CEO believes holds significant value for the merger's potential in the immunology and inflammation sector.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ISS And Glass Lewis Support Ikena's Share Issuance For Proposed Inmagene Merger

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

High Short Interest in U.S. Electrical Sector, Plug Power at 25.36%

Intuitive Machines CEO Stephen Altemus Sells 12,669 Shares for Approximately $253,400

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch